Septerna, Inc. (SEPN)
| Market Cap | 1.89B +92.3% |
| Revenue (ttm) | 98.88M +13,520.1% |
| Net Income | -24.24M |
| EPS | -0.54 |
| Shares Out | 46.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200,302 |
| Open | 40.63 |
| Previous Close | 40.88 |
| Day's Range | 39.65 - 41.21 |
| 52-Week Range | 17.55 - 51.10 |
| Beta | 2.28 |
| Analysts | Strong Buy |
| Price Target | 54.22 (+34.18%) |
| Est. Earnings | Nov 9, 2026 |
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM f... [Read more]
Financial Performance
In 2025, Septerna's revenue was $45.95 million, an increase of 4174.51% compared to the previous year's $1.08 million. Losses were -$48.88 million, -31.92% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for SEPN stock is "Strong Buy." The 12-month stock price target is $54.22, which is an increase of 34.18% from the latest price.
News
3 Small-Cap Stocks Analysts Expect to Rally over 35%
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Progress Software ($PRGS), and AngioDynamics ($ANGO) as companies...
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of...
Septerna Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company is advancing a GPCR-focused pipeline with SEP-479 in phase I for hypoparathyroidism, supported by strong financials and a Novo Nordisk partnership. Key programs target endocrine and metabolic diseases, with strategic plans for global commercialization and innovative trial designs.
Septerna Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is advancing an oral PTH receptor agonist for hypoparathyroidism, with full phase I data expected in Q1 next year, and is expanding its pipeline with programs in Graves' disease, osteoporosis, and mast cell diseases. Regulatory changes and platform innovations are enabling faster, more efficient development.
Septerna to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug dis...
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug disc...
Septerna price target raised to $48 from $38 at JPMorgan
JPMorgan raised the firm’s price target on Septerna (SEPN) to $48 from $38 and keeps an Overweight rating on the shares.
Septerna price target raised to $60 from $40 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Septerna (SEPN) to $60 from $40 and keeps a Buy rating on the shares post the Q2 report. The firm says SEP-479…
Septerna price target raised to $62 from $43 at Jones
Jones analyst Catherine Novack raised the firm’s price target on Septerna (SEPN) to $62 from $43 and keeps a Buy rating on the shares. The company reported Q2 earnings and…
Septerna price target raised to $49 from $45 at Raymond James
Raymond James raised the firm’s price target on Septerna (SEPN) to $49 from $45 and keeps a Strong Buy rating on the shares. The firm updated its model post the…
Septerna price target raised to $51 from $45 at Guggenheim
Guggenheim raised the firm’s price target on Septerna (SEPN) to $51 from $45 and keeps a Buy rating on the shares. The firm is increasing its view of the odds…
Septerna reports Q2 EPS (29c), consensus (49c)
Reports Q2 revenue $26.75M, consensus $19.22M. “We continue to make meaningful progress across our portfolio as we execute on our strategy to develop differentiated oral medicines targeting GPCRs,” sa...
Septerna Quarterly report: Q2 2026
Septerna has published its Q2 2026 quarterly earnings report on August 10, 2026.
Septerna Earnings release: Q2 2026
Septerna released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Septerna Slides: Investor presentation
Septerna has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
3 Small-Cap Stocks Analysts Expect to Rally Big
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Kornit Digital ($KRNT), and AngioDynamics ($ANGO) as companies wi...
3 Small-Cap Stocks with ‘Strong Buy’ Ratings and 40%+ Upside, According to Analysts
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Kornit Digital ($KRNT), and AngioDynamics ($ANGO) as companies wi...
Septerna price target raised to $43 from $35 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Septerna (SEPN) to $43 from $35 and keeps a Buy rating on the shares. Investor focus is shifting toward the…
Septerna price target lowered to $45 from $52 at Guggenheim
Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Septerna (SEPN) to $45 from $52 and keeps a Buy rating on the shares after Evommune (EVMN) announced top-line results…
Septerna Transcript: AGM 2026
The meeting saw the election of two directors and ratification of the auditor, with all proposals approved. Key pipeline programs advanced, including SEP-479 and SEP-631, and strong financials were reported with $522 million in cash. Strategic partnerships and future clinical milestones were highlighted.
Septerna initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Septerna (SEPN) with a Buy rating and $52 price target
Septerna to present preclinical characterization of SEP-479
Septerna (SEPN) announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society’s Annual Meeting, taking place June 1...
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today anno...
Septerna price target raised to $53 from $47 at Raymond James
Raymond James raised the firm’s price target on Septerna (SEPN) to $53 from $47 and keeps a Strong Buy rating on the shares. The firm sees Septerna as “among the…
3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Kornit Digital ($KRNT), and AngioDynamics ($ANGO) as companies wi...